ArticleJCO precision oncology2022
Clinical Utility of Genomic Testing in Cancer Care.
Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Are we properly evaluating genetic and genomic testing? A systematic review of health technology assessment reports.Journal of translational medicine · 2025Pooled it
- Access to Guideline-Concordant Oncology Genomic Testing: A Qualitative Study of Black Cancer Patients and Oncology Providers.Current oncology (Toronto, Ont.) · 2026Article
- Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data.Clinical and translational science · 2026Article
- Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026Review
- Genetics services in Latin America: a descriptive study of availability and utilization of genetics in healthcare.Journal of community genetics · 2025Article
- Review
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Real-World Technical Hurdles of ctDNA NGS Analysis: Lessons from Clinical Implementation.Diseases (Basel, Switzerland) · 2025Article
- Need Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study.JMIR human factors · 2025Article
- Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.Future oncology (London, England) · 2025Review
- Immune checkpoint inhibitor associated lichenoid dermatitis mimicking erythema multiforme major with a germline variant in human leukocyte antigen-B15.JAAD case reports · 2025Article
- Recommendations for pharmacogenetic testing in clinical practice guidelines in the US.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2024Review
- Deep learning in cancer genomics and histopathology.Genome medicine · 2024Review
- Construction and optimization of multi-platform precision pathways for precision medicine.Scientific reports · 2024Article
- Editorial: Recent developments in clinical biomarkers for cancer prognosis, prediction, treatment, and their clinical utility.Frontiers in genetics · 2024Article
- The molecular tumor board as a step in cancer patient management: a southern Italian experience.Frontiers in medicine · 2024Article
- Variability in conceptualizations and measurement of genetic literacy.PEC innovation · 2023Article
- Evolution of predictive risk factor analysis for chemotherapy-related toxicity.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies.JCO precision oncology · 2023Article
- Computational pathology in cancer diagnosis, prognosis, and prediction - present day and prospects.The Journal of pathology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn the era of personalized medicine, physicians rely on their understanding of clinical utility to assess the value of rapidly evolving genetic and genomic tests. Current definitions of the clinical utility of genetic testing sufficiently capture a range of benefits and risks that derive from positive and negative results of tests that assess one gene or a few genes. However, these definitions of clinical utility are inadequate to recognize the wider scope of benefits that accrue from more comprehensive genomic tests, which can develop data sets that inform clinical decision making as well as population health and scientific advancement in novel ways.
methodsAn expert roundtable discussion with leaders from multiple sectors of the health care ecosystem was convened to develop a contemporary, fuller definition of the clinical utility of genomic testing in cancer care.
resultsWe present an updated definition and offer recommendations for successful implementation.
conclusionApplying this expanded definition will encourage evidence-based use of genomic testing in cancer care by helping physicians and other health care decision makers account for the broader range of benefits and risks of testing for individual patients, health systems, population health, and scientific advancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.